All In Biotech

Drug Trial Radar · NCT06938269

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWN109 Tablets in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 18, 2025

Primary completion

Mar 2026

Study completion May 2026

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.

Conditions

  • Overweight or Obesity

Interventions

  • MWN109 tabletDrug

    Strength: 4mg, 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.

  • PlaceboDrug

    Administration: Oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Incidence of treatment emergent adverse events (TEAEs) following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
  2. Number of participants with change in laboratory parameters following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
  3. Number of participants with change in 12-lead ECG following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
  4. Number of participants with change in Vital signs following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
  5. Incidence of anti-drug antibody (ADA) formation following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
  6. Number of participants with change in physical examinations following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia · Recruiting

  • Veritus Research

    Bayswater, Victoria, Australia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.